Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis

  title={Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis},
  author={Mark M. Janko and Jonah Joffe and Danielle Michael and Lauren Earl and Katherine L Rosettie and Gianna W. Sparks and Samuel B. Albertson and Kelly Compton and Paola Pedroza Velandia and Lauryn Stafford and Peng Zheng and Aleksandr Y. Aravkin and Hmwe H. Kyu and Christopher J. L. Murray and Marcia R. Weaver},
  pages={3903 - 3917}
1 Citations

Figures and Tables from this paper

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: a modelling study

TB vaccination would be highly impactful and cost-effective in most LMICs, and introduction of an adolescent/adult vaccine could produce $258-447 billion in economic benefits by 2050.



Cost-effectiveness of HPV vaccination in 195 countries: A meta-regression analysis

Cost-effectiveness analysis (CEA) is a well-known, but resource intensive, method for comparing the costs and health outcomes of health interventions. To build on available evidence, researchers are

Systematic Review and Meta-Analysis of Cost-effectiveness of Rotavirus Vaccine in Low-Income and Lower-Middle-Income Countries

Rotavirus vaccine would be cost-effective to introduce in LICs and LMICs and could aid decision makers and provide evidence for introduction of rotavirus vaccination.

Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years

It is suggested that prioritizing vaccine introduction and interventions to reduce diarrhea-associated morbidity and mortality is necessary in the continued global reduction of rotavirus infection.

A Systematic Review of the Effect of Rotavirus Vaccination on Diarrhea Outcomes Among Children Younger Than 5 Years

The findings confirm the protective efficacy and effectiveness of rotav virus vaccination against rotavirus diarrheal outcomes among children under 5 globally.

The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe.

A Systematic Review of Economic Evaluation Methodologies Between Resource-Limited and Resource-Rich Countries: A Case of Rotavirus Vaccines

The quality of economic evaluations in LMICs was not as high as those from HICs, but it is of an acceptable level given several limitations that exist in these settings.

A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted

A large number of the studies in Sub-Saharan Africa addressed high-burden conditions such as HIV/AIDS, tuberculosis, neglected tropical diseases and malaria, and diarrhea, lower respiratory infections, meningitis, and other common infectious diseases.

Thresholds for the cost–effectiveness of interventions: alternative approaches

It is argued that reliance on WHO-CHOICE thresholds reduces the value of cost–effectiveness analyses and makes such analyses too blunt to be useful for most decision-making in the field of public health.